{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:15:53Z","timestamp":1793103353089,"version":"4.5.0"},"reference-count":46,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Inflammatory bowel disease (IBD) is a condition characterized by chronic intestinal inflammation. We can identify two major forms: Crohn\u2019s disease (CD) and ulcerative colitis (UC). One of the extraintestinal manifestations of IBD is nonalcoholic fatty liver disease (NAFLD). IBD and NAFLD share common pathogenetic mechanisms. Ultrasound (US) examination is the most commonly used imaging method for the diagnosis of NAFLD. This cross-sectional observational retrospective study aimed to evaluate the US prevalence of NAFLD in IBD patients and their clinical features. Materials and Methods: A total of 143 patients with IBD underwent hepatic US and were divided into two different groups according to the presence or absence of NAFLD. Subsequently, new exclusion criteria for dysmetabolic comorbidities (defined as plus) were applied. Results: The US prevalence of NAFLD was 23% (21% in CD and 24% in UC, respectively). Most IBD\u2013NAFLD patients were male and older and showed significantly higher values for body mass index, waist circumference, disease duration, and age at onset than those without NAFLD. IBD\u2013NAFLD patients showed a significantly higher percentage of stenosing phenotype and left-side colitis. Regarding metabolic features, IBD\u2013NAFLD patients showed a significantly higher percentage of hypertension and IBD plus dysmetabolic criteria. Also, higher values of alanine aminotransferase and triglycerides and lower levels of high-density lipoproteins are reported in these patients. Conclusions: We suggest performing liver US screening in subjects affected by IBD to detect NAFLD earlier. Also, patients with NAFLD present several metabolic comorbidities that would fall within the new definition of metabolic-associated fatty liver disease. Finally, we encourage larger longitudinal studies, including healthy controls, to provide further confirmation of our preliminary data.<\/jats:p>","DOI":"10.3390\/medicina59111935","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T03:29:33Z","timestamp":1698809373000},"page":"1935","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-1524","authenticated-orcid":false,"given":"Ludovico","family":"Abenavoli","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, Viale Europa, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-4644","authenticated-orcid":false,"given":"Rocco","family":"Spagnuolo","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, Viale Europa, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7084-8264","authenticated-orcid":false,"given":"Giuseppe Guido Maria","family":"Scarlata","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, Viale Europa, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2101-1118","authenticated-orcid":false,"given":"Emidio","family":"Scarpellini","sequence":"additional","affiliation":[{"name":"Translationeel Onderzoek van Gastroenterologische Aandoeningen (T.A.R.G.I.D.), Gasthuisberg University Hospital, KU Leuven, Herestraat 49, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2017-4270","authenticated-orcid":false,"given":"Luigi","family":"Boccuto","sequence":"additional","affiliation":[{"name":"Healthcare Genetics and Genomics Doctoral Program, School of Nursing, College of Behavioral, Social and Health Sciences, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5120-1046","authenticated-orcid":false,"given":"Francesco","family":"Luzza","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, Viale Europa, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Spagnuolo, R., Larussa, T., Iannelli, C., Cosco, C., Nistic\u00f2, E., Manduci, E., Bruno, A., Boccuto, L., Abenavoli, L., and Luzza, F. (2020). COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey. Medicina, 56.","DOI":"10.3390\/medicina56080407"},{"key":"ref_2","unstructured":"Malik, T.F., and Aurelio, D.M. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105206","DOI":"10.1016\/j.phrs.2020.105206","article-title":"Extra-intestinal manifestations of inflammatory bowel diseases","volume":"161","author":"Marotto","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Dom\u00ednguez, S.J., Garc\u00eda-Mateo, S., Laredo, V., Gargallo-Puyuelo, C.J., Gallego Llera, B., L\u00f3pez de la Cruz, J., and Gomoll\u00f3n, F. (2023). Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers, 15.","DOI":"10.3390\/cancers15133367"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Giubilei, L., Procopio, A.C., Spagnuolo, R., Luzza, F., Boccuto, L., and Scarpellini, E. (2022). Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay. Nutrients, 14.","DOI":"10.3390\/nu14245323"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/MIB.0000000000001085","article-title":"Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease among Patients with Inflammatory Bowel Disease","volume":"23","author":"Glassner","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Scarlata, G.G.M., Scarpellini, E., Boccuto, L., Spagnuolo, R., Tilocca, B., Roncada, P., and Luzza, F. (2023). Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome. Medicina, 59.","DOI":"10.3390\/medicina59030594"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Spagnuolo, R., Montalcini, T., De Bonis, D., Ferro, Y., Cosco, C., Mazza, E., Romeo, S., Doldo, P., and Pujia, A. (2019). Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. Nutrients, 11.","DOI":"10.3390\/nu11020303"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hong, Q., Shen, J., Feng, Q., Zheng, Q., and Qiao, Y. (2022). Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn\u2019s disease. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02238-5"},{"key":"ref_10","first-page":"5818","article-title":"Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: A systematic review","volume":"25","author":"Spagnuolo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/ibd\/izy051","article-title":"Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors","volume":"24","author":"Principi","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ibd\/izaa189","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"27","author":"Lin","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.3748\/wjg.v22.i34.7727","article-title":"Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article","volume":"22","author":"Chao","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_14","first-page":"357","article-title":"Gut microbiota in inflammatory bowel disease: A target for therapy not to be missed","volume":"67","author":"Larussa","year":"2021","journal-title":"Minerva Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MIB.0000000000000569","article-title":"PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes","volume":"22","author":"Mancina","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease","volume":"22","author":"Bessissow","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"otad004","DOI":"10.1093\/crocol\/otad004","article-title":"Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases","volume":"5","author":"Kablawi","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"ref_18","first-page":"406","article-title":"Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors","volume":"21","author":"Calleja","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/SGA.0000000000000461","article-title":"Ulcerative Colitis as an Independent Risk Factor for Hepatic Steatosis","volume":"43","author":"Mancina","year":"2020","journal-title":"Gastroenterol. Nurs. Off. J. Soc. Gastroenterol. Nurses Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3109\/00365521.2014.921326","article-title":"National trends and inpatient outcomes of inflammatory bowel disease patients with concomitant chronic liver disease","volume":"49","author":"Nguyen","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1111\/j.1572-0241.2007.01526.x","article-title":"The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation","volume":"102","author":"Hamaguchi","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/1574887109666141216102231","article-title":"The role of liver biopsy to assess non-alcoholic fatty liver disease","volume":"9","author":"Kobyliak","year":"2014","journal-title":"Rev. Recent. Clin. Trials"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1665-2681(19)31021-X","article-title":"Transient elastography in non-alcoholic fatty liver disease","volume":"11","author":"Abenavoli","year":"2012","journal-title":"Ann. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4292\/wjgpt.v7.i1.91","article-title":"Clinical applications, limitations and future role of transient elastography in the management of liver disease","volume":"7","author":"Chang","year":"2016","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., and Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord., 22.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/jum.16048","article-title":"Interobserver Variability in Ultrasound-Based Liver Fat Quantification","volume":"42","author":"Cerit","year":"2023","journal-title":"J. Ultrasound Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/apt.16879","article-title":"Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"55","author":"Zamani","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_29","first-page":"463","article-title":"High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.14309\/01.ajg.0000798796.64423.34","article-title":"P049 Investigation of Liver Diseases by Ultrasound in Patients with Inflammatory Bowel Disease","volume":"116","author":"Shintaku","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.3748\/wjg.v25.i40.6053","article-title":"Ultrasound-based techniques for the diagnosis of liver steatosis","volume":"25","author":"Ferraioli","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1016\/j.cgh.2021.02.015","article-title":"Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy","volume":"19","author":"Angelico","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/hepr.12828","article-title":"Significance of non-alcoholic fatty liver disease in Crohn\u2019s disease: A retrospective cohort study","volume":"47","author":"Sagami","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.crohns.2012.10.015","article-title":"Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"7","author":"Sourianarayanane","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ecco-jcc\/jjz203.291","article-title":"P162 Prevalence of NAFLD (nonalcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: The impact of traditional risk factors, intestinal inflammation and genetic phenotype","volume":"14","author":"Scrivo","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.3748\/wjg.v25.i37.5676","article-title":"Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history","volume":"25","author":"Paduano","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.3748\/wjg.v26.i46.7367","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis","volume":"26","author":"Hoffmann","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ibd\/izy200","article-title":"Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography","volume":"25","author":"Restellini","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41419-017-0124-2","article-title":"Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease","volume":"9","author":"Sartini","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5009\/gnl210118","article-title":"Long-term Disease Course of Crohn\u2019s Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors","volume":"16","author":"Cho","year":"2022","journal-title":"Gut Liver"},{"key":"ref_43","first-page":"e42995","article-title":"Crohn\u2019s Disease is a Greater Risk Factor for Nonalcoholic Fatty Liver Disease Compared to Ulcerative Colitis: A Systematic Review","volume":"15","author":"Kodali","year":"2023","journal-title":"Cureus"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/ecco-jcc\/jjab212","article-title":"Inflammatory Bowel Disease-associated Fatty Liver Disease: The Potential Effect of Biologic Agents","volume":"16","author":"Papaefthymiou","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"i837","DOI":"10.1093\/ecco-jcc\/jjac190.0834","article-title":"The effect of anti-TNF-\u03b1 and anti-integrin agents on liver steatosis in inflammatory bowel disease patients with non-alcoholic fatty liver disease","volume":"17","author":"Mitrovic","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.metop.2021.100149","article-title":"Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)","volume":"12","author":"Zarghamravanbakhsh","year":"2021","journal-title":"Metabol. Open"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/11\/1935\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:27Z","timestamp":1760130927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/11\/1935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["medicina59111935"],"URL":"https:\/\/doi.org\/10.3390\/medicina59111935","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}